down arrow

Harbin Pharmaceutical Group Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE0000009T3
  • SHG: 600664
CNY
9.04
-0.04 (-0.44%)

Sep 23

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Harbin Pharmaceutical Group Co., Ltd.

Why is Harbin Pharmaceutical Group Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 8.92%
  • The company has been able to generate a Return on Capital Employed (avg) of 8.92% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of 7.28% and Operating profit at 21.67% over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 9.35% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 7.28% and Operating profit at 21.67% over the last 5 years
4
Positive results in Jun 26
  • RAW MATERIAL COST(Y) Fallen by -5.06% (YoY)
  • CASH AND EQV(HY) Highest at CNY 6,566.71 MM
  • INVENTORY TURNOVER RATIO(HY) Highest at 6.28 times
5
With ROE of 5.82%, it has a fair valuation with a 1.26 Price to Book Value
  • Over the past year, while the stock has generated a return of 151.52%, its profits have fallen by -52.6%
6
Market Beating performance in long term as well as near term
  • Along with generating 151.52% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Harbin Pharmaceutical Group Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harbin Pharmaceutical Group Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Harbin Pharmaceutical Group Co., Ltd.
153.93%
3.88
58.45%
China Shanghai Composite
3.0%
0.22
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
7.28%
EBIT Growth (5y)
21.67%
EBIT to Interest (avg)
10.28
Debt to EBITDA (avg)
0.85
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
1.86
Tax Ratio
32.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.74%
ROE (avg)
9.35%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
1.26
EV to EBIT
14.05
EV to EBITDA
9.86
EV to Capital Employed
1.28
EV to Sales
0.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.10%
ROE (Latest)
5.82%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -5.06% (YoY

CASH AND EQV(HY)

Highest at CNY 6,566.71 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 6.28 times

OPERATING PROFIT(Q)

Highest at CNY 350.49 MM

OPERATING PROFIT MARGIN(Q)

Highest at 8.51 %

PRE-TAX PROFIT(Q)

Highest at CNY 311.43 MM

NET PROFIT(Q)

Highest at CNY 249.19 MM

EPS(Q)

Highest at CNY 0.1

-2What is not working for the Company
INTEREST(Q)

At CNY 10.1 MM has Grown at 26.15%

Here's what is working for Harbin Pharmaceutical Group Co., Ltd.

Pre-Tax Profit
At CNY 311.43 MM has Grown at 145.46%
over average net sales of the previous four periods of CNY 126.87 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 249.19 MM has Grown at 221.74%
over average net sales of the previous four periods of CNY 77.45 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Profit
Highest at CNY 350.49 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin
Highest at 8.51 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at CNY 311.43 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 249.19 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS
Highest at CNY 0.1
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Cash and Eqv
Highest at CNY 6,566.71 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio
Highest at 6.28 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -5.06% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Harbin Pharmaceutical Group Co., Ltd.

Interest
At CNY 10.1 MM has Grown at 26.15%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Footer loading